Do you need a Texas-based partner for your CPRIT grant?
Interested in our services?

Our Story

Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies specializing in cancer immunotherapy. Founded by industry pioneer Dr. George Peoples, Cancer Insight offers exceptional CRO services within an academic ecosystem built to provide value and insight beyond expectation.  Our team delivers an experienced foundation grounded in decades of scientific research and business management.  We are dedicated to eradicating cancer through the discovery of safe and effective treatments to prevent the recurrence of cancer.

About Cancer Insight

Headquartered in San Antonio, Texas, Cancer Insight is a boutique contract research organization and drug development consulting firm focused on discovering innovative solutions in the cancer immunotherapy field. With our deep background in the science of cancer immunotherapy, we deliver an academic foundation to your research needs.  We approach every project from a scientific and academic perspective as well as a strategic business perspective to help our clients develop sound research models to achieve effective results with highly targeted endpoints based on needs and expectations.

Our experience and expertise delivers a high value proposition to build and execute your project effectively and efficiently.

Cancer Insight was founded by Dr. George Peoples after his retirement from the US Military, where he established the Cancer Vaccine Development Program.  We have brought together decades of academic experience with business professionals in the private sector to offer CRO services that go beyond expectation.

Our Focus

At Cancer Insight, we are committed to finding new and innovative ways to treat cancer, specializing in immunotherapy to prevent the recurrence of certain types of cancer.

Cancer immunotherapy works by leveraging the body’s own immune system to seek out and attack cancer cells. Our mission is to eradicate cancer through the innovative use of immunotherapy. We are selective in the research that we undertake, committing ourselves to a specific body of research with the goal of preventing cancer through immunotherapy as the ultimate way to eradicate the disease.

About CVDP: In 2000 during his tenure with the US Army, COL (ret) George Peoples, M.D. founded the Cancer Vaccine Development Program (CVDP), a research network for scientific investigation of potential vaccines against cancer of all types.  The CVDP under Dr. Peoples’ leadership has made incredible advances in the field of cancer immunotherapy and vaccine development.  One such accomplishment is the first ever adjuvant breast cancer vaccine developed by Dr. Peoples. This vaccine shows great promise as it is being tested in the only phase III breast cancer vaccine trial currently in the US

The CVDP has an extensive history including 29 cancer clinical trials, enrollment of over 700 cancer patients, and over 5,000 cancer vaccine inoculations.  Currently, five of our vaccines, E75, GP2, E39, E39’, and AE37 have been licensed out to industry partners.

The CVDP is currently being reconstituted within the [Metis Foundation, Inc.], a San Antonio non-profit foundation created to advance clinically relevant scientific research to the medical community, especially within the Department of Defense.